Questions and answers
Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
- Written questions must be answered within 10 working days (20 working days during recess)
- Other questions such as Topical, Portfolio, General and First Minister's Question Times are taken in the Chamber
Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.
Filter your results Hide all filters
Displaying 1015 questions Show Answers
Question reference: S4W-07026
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Tuesday, 01 May 2012
- Current Status: Answered by Nicola Sturgeon on 14 May 2012
To ask the Scottish Executive how many (a) successful and (b) unsuccessful individual patient treatment requests for pharmacological treatments have been made in each year since 1999, also broken down by (i) NHS board area and (ii) associated indication.
Answer
Question reference: S4W-06393
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Thursday, 29 March 2012
- Current Status: Answered by Nicola Sturgeon on 24 April 2012
To ask the Scottish Executive how much the Hospital Medicines Utilisation Database recorded as being spent on cancer medicines in 2011, also broken down by NHS board.
Answer
Question reference: S4W-06395
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Thursday, 29 March 2012
- Current Status: Answered by Nicola Sturgeon on 24 April 2012
To ask the Scottish Executive how much the NHS spent on (a) proton pump inhibitors, (b) statins and (c) laxatives in 2011.
Answer
Question reference: S4W-06389
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Thursday, 29 March 2012
- Current Status: Answered by Nicola Sturgeon on 24 April 2012
To ask the Scottish Executive what information is held (a) centrally and (b) by each NHS board on the use of (i) bevacizumab, (ii) cetuximab, (iii) lapatinib, (iv) abiraterone, (v) everolimus, (vi) rituximab, (vii) sorafenib, (viii) bendamustine, (ix) fulvestrant and (x) bortezomib in the treatment of cancer.
Answer
Question reference: S4W-06538
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Friday, 30 March 2012
- Current Status: Answered by Nicola Sturgeon on 23 April 2012
To ask the Scottish Executive how many training places in community sexual and reproductive health have been allocated to consultants in each of the last five years, broken down by NHS board.
Answer
Question reference: S4W-06539
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Friday, 30 March 2012
- Current Status: Answered by Nicola Sturgeon on 23 April 2012
To ask the Scottish Executive how many consultants are currently undergoing training in community sexual and reproductive health, broken down by (a) the year that the training commenced and (b) NHS board.
Answer
Question reference: S4W-06540
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Friday, 30 March 2012
- Current Status: Answered by Nicola Sturgeon on 23 April 2012
To ask the Scottish Executive how many trained consultants there have been in community sexual and reproductive health in each of the last five years, broken down by NHS board.
Answer
Question reference: S4W-06543
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Friday, 30 March 2012
- Current Status: Answered by Nicola Sturgeon on 23 April 2012
To ask the Scottish Executive whether the multiple sclerosis drug, Fingolimod, is (a) approved by the Scottish Medicines Consortium and (b) available in the NHS.
Answer
Question reference: S4W-06400
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Thursday, 29 March 2012
- Current Status: Answered by Nicola Sturgeon on 23 April 2012
To ask the Scottish Executive whether it will conduct a review of the impact of the guidance that was issued in March 2011 on individual patient treatment requests and, if so, when.
Answer
Question reference: S4W-06397
- Asked by: Jackson Carlaw, MSP for West Scotland, Scottish Conservative and Unionist Party
- Date lodged: Thursday, 29 March 2012
- Current Status: Answered by Nicola Sturgeon on 23 April 2012
To ask the Scottish Executive what steps it will take to ensure that patients with a cancer that has spread will receive equitable access to the same medicines as patients in England.